Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer

NCT04814875 is registered in ClinicalTrials.gov with THERAPIM PTY LTD as lead sponsor.

NCT NCT04814875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04814875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Lead sponsor
THERAPIM PTY LTD
Phase
Phase 1/2
Overall status
Terminated
Start date
September 1, 2021
Completion date
November 30, 2023
Enrollment
16 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, high grade serious or endometrioid carcinoma of the ovary, fallopian tube, or primary peritoneal cancer, ovarian cancer, primary peritoneal carcinoma